证券代码：301408 证券简称：华人健康 安徽华人健康医药股份有限公司 投资者关系活动记录表 编号：2025-005 投资者关系活动类别 特定对象调研 ☐ 分析师会议 ☐ 媒体采访 ☐ 业绩说明会 ☐ 新闻发布会 ☐ 路演活动 现场参观 ☐ 其他 参与单位名称及人 员姓名 兴业证券等投资者一行 时间 2025年12月12日14:00-16:00 地点 公司会议室、展厅及园区内各子公司 上市公司接待人员姓 名 董事长、总裁 何家乐先生 董事会秘书、财务总监 李梅女士 证券事务代表 黄莲莲女士 投资者关系活动主要 内容介绍 一、介绍环节 公司董事长、总裁何家乐先生就公司2025年前三季度经营情况及未来发 展规划做了介绍。 2025年前三季度，公司坚定推进"1234战略"，成效显著，各业务板块 协同增效，实现公司营收与利润的双增长。 2025年前三季度，公司实现营业收入38.92亿元，同比增长19.06%；归属 于上市公司股东的净利润为1.57亿元，同比增长45.21%；归属于上市公司股 东的扣除非经常性损益的净利润为1.51亿元，同比增长51.00%。 面对新时代、新格局、新环境等挑战，公司将以政策为导向，以市 ...

Financial Performance - In 2024, the company achieved a record revenue of 4.532 billion CNY, a year-on-year increase of 19.34% [3] - The net profit attributable to the parent company was 138 million CNY, up 20.09% from the previous year [3] - In Q1 2025, revenue reached 1.267 billion CNY, reflecting a 14.71% increase year-on-year [3] - The net profit for Q1 2025 was 61.22 million CNY, marking a 28.15% growth compared to the same period last year [3] Strategic Initiatives - The significant growth is attributed to the "dual-driven, full-chain symbiosis" strategy, focusing on optimizing business structure and enhancing innovation [3] - The company is actively expanding in the elderly health sector, providing chronic disease training and services through pharmacies [4] - Development of the "Fuman Medical" series targeting common diseases in the elderly, alongside the "Guojin" series of traditional Chinese medicine products [4] Brand Development - The company has established a comprehensive self-owned brand system with over 700 agency products covering various medical categories [5] - The "Shenhua Weikang" product line has seen substantial sales growth, indicating strong market potential [5] - The company is expanding its online retail presence through platforms like Douyin, JD, Tmall, and Pinduoduo [5] Market Expansion - The company plans to deepen its market presence in Zhejiang and Fujian, focusing on both existing advantages and new growth opportunities [6] - The "1234 strategy" aims to enhance collaboration across four major business platforms, creating a cohesive pharmaceutical health ecosystem [7] Future Outlook - The company will continue to expand its store network through new openings, acquisitions, and franchises, solidifying its leading position in Anhui [8] - Emphasis on balanced development across core business segments while enhancing brand influence and market share [8] - Ongoing commitment to digital transformation and operational efficiency to support high-quality growth [8]